3 News & Press Releases found
Atriva Therapeutics GmbH News
-
Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron
Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concernProf. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board The findings underscore the importance of new ...
-
Atriva Therapeutics announces changes in its Management Team
Prof. Oliver Planz to step down as CSO at Atriva by mid-year 2022 Prof. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development ...
-
Atriva Therapeutics receives U.S. FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections
FDA Orphan Drug Designation (ODD) underscores strength of Atriva’s pipeline and high need for treatments for rare and neglected tropical diseases ODD allows Atriva to benefit from various incentives to develop zapnometinib (ATR-002) against ...